『WolverHeme Happy Hour』のカバーアート

WolverHeme Happy Hour

著者： Bernard Marini Anthony Perissinotti et al.
無料で聴く

  • サマリー

  • Welcome to WolverHeme Happy Hour! This is a podcast dedicated to all things hematology! We discuss new data, debate controversial therapies, and talk about new and exciting research. While we nerd out about data, we'll have a few drinks! Disclaimer: The views and opinions expressed on this podcast are solely those of the podcasters and guests and do not reflect the views or opinions of our employers or other affiliations.
    Bernard Marini, Anthony Perissinotti, et al.
    続きを読む 一部表示
エピソード
  • Episode 24: Myeloma Madness with the Myeloma Man

    Episode 24: Myeloma Madness with the Myeloma Man
    2024/04/17

    In this episode, Anthony and Bernie are joined by Multiple Myeloma expert Dr. Manni Mohyuddin, to discuss the recent FDA approval updates of CAR-T in this disease state. We also discuss the hotly debated topic of MRD as a surrogate endpoint for accelerated approval in Myeloma.

    続きを読む 一部表示
    59 分
  • Anthony and Bernie get rich on no-larabine! An ASH 2023 ALL discussion

    Anthony and Bernie get rich on no-larabine! An ASH 2023 ALL discussion
    2024/01/25

    In this episode, Anthony and Bernie review the most impactful and interesting ALL abstracts at the 2023 ASH Annual Meeting. We dive into the nelarabine abstracts, calaspargase (cal-peg), and the evolution of the treatment of Ph+ ALL!


    Abstracts discussed:

    • https://ash.confex.com/ash/2023/webprogram/Paper190141.html - COG AYA Outcomes (and silly nelarabine conclusions)
    • https://ash.confex.com/ash/2023/webprogram/Paper177696.html - ATRIALL Nelarabine study
    • https://ash.confex.com/ash/2023/webprogram/Paper179562.html - HyperCVAD + Nelarabine + PEG + venetoclax
    • https://ash.confex.com/ash/2023/webprogram/Paper179192.html - ALL-TARGET Study in R/R T-ALL
    • https://ash.confex.com/ash/2023/webprogram/Paper187694.html - Cal-PEG is toxic
    • https://ash.confex.com/ash/2023/webprogram/Paper188064.html - Ponatinib + Blinatumomab
    • https://ash.confex.com/ash/2023/webprogram/Paper187773.html - D-ALBA (Dasatinib + Blinatumomab)
    • https://ash.confex.com/ash/2023/webprogram/Paper189632.html - GIMEMA (Dasatinib or Ponatinib + Blinatumomab)
    続きを読む 一部表示
    58 分
  • LymphOMG: Pouring Over Lymphoma Abstracts from ASH

    LymphOMG: Pouring Over Lymphoma Abstracts from ASH
    2023/12/29

    OMG! In this extra fun holiday episode, we are joined by lymphoma experts Tycel Phillips and Aaron Goodman to review the most impactful and controversial lymphoma abstracts from ASH! Stay tuned for a lively discussion!


    Abstracts Discussed!

    1. SYMPATICO (Ibrutinib + Ven in R/R MCL): https://ash.confex.com/ash/2023/webprogram/Paper191921.html
    2. Nivo-AVD in elderly Hodgkin Lymphoma: https://ash.confex.com/ash/2023/webprogram/Paper180114.html
    3. BOVEN - Zanubrutinib + Obi + Ven in TP53 mutant MCL: https://ash.confex.com/ash/2023/webprogram/Paper180069.html
    4. CAR-T in CNS Lymphoma: https://ash.confex.com/ash/2023/webprogram/Paper174883.html (EBMT data), https://ash.confex.com/ash/2023/webprogram/Paper184345.html (Multicenter retrospective study)
    5. Synthetic Control Arms: https://ash.confex.com/ash/2023/webprogram/Paper177708.html
    6. POLARIX Subgroup Analysis (shout out to the Blood Cancer Talks crew!): https://x.com/Eddie_Cliff/status/1733901400822993257?s=20
    続きを読む 一部表示
    1 時間 13 分

あらすじ・解説

Welcome to WolverHeme Happy Hour! This is a podcast dedicated to all things hematology! We discuss new data, debate controversial therapies, and talk about new and exciting research. While we nerd out about data, we'll have a few drinks! Disclaimer: The views and opinions expressed on this podcast are solely those of the podcasters and guests and do not reflect the views or opinions of our employers or other affiliations.
Bernard Marini, Anthony Perissinotti, et al.
身体的病い・疾患 衛生・健康的な生活
続きを読む 一部表示

WolverHeme Happy Hourに寄せられたリスナーの声

カスタマーレビュー：以下のタブを選択することで、他のサイトのレビューをご覧になれます。

Audible.co.jp

Amazon.co.jp
レビューはまだありません。